Innorna and BeiGene launched a strategic cooperation to jointly develop innovative mRNA products
Faced with the challenge of delivering mRNA into the correct cell, mRNA carriers have long been unable to maximize mRNA as a therapeutic tool capable of guiding cells to generate disease-fighting proteins. Innorna was able to develop the proprietary diversity-oriented LNP platform for safely and effectively delivering the mRNA into the right cells and commercializing this innovative technology. This enables a wide range of potential prophylactic and therapeutic strategies that we are using to advance a diversified portfolio of mRNA medicine pipelines．
Innorna has analyzed and optimized the synthesized LNP structure and activity data, simulated the nucleic acid drug delivery and therapeutic effect with high-throughput screening, and screened out the best-in-class LNP structures for specific needs. Since its establishment, Innorna has built a resource library containing over 5,000 LNPs for various treatment approaches.
messenger RNA (mRNA) is a type of single-strand ribonucleic acid that is transcribed from DNA (deoxyribonucleic acid). It carries genetic information and can guide protein synthesis. The mechanism of nucleic acid drugs is to send the modified mRNA molecules into the cytoplasm and generate the required proteins within target cells. In theory, mRNA can express any protein and, therefore, can prevent or treat almost all protein-based diseases, including infectious diseases, various types of cancer, autoimmune diseases, and some rare diseases. Importantly, mRNA acts as a link connecting DNA and proteins, and the development of drugs with mRNA targets is expected to resolve many of the limitations and challenges encountered in traditional drug development of “untargetable” and “unmanufacturable” drugs.
Innorna and PATH are exploring innovative mRNA vaccine technologies aiming to make such innovations more widely accessible.
ZFSW: Carrying out technical cooperation with Innorna, targeting mRNA R&D projects
Molecular diversity is the key to finding new functionalities of lipid nanoparticles. Innorna is committed to building a diversity-oriented lipid library (DOLL) to explore new functions of lipids, such as tissue specific delivery and molecules with low immunogenicity. By employing various chemical methods to build up the core structure of DOLL, we have successfully established a broad spectrum of molecular diversity, which significantly optimize the opportunities of finding new functional lipids than that from combinatorial libraries.
Innorna has become a platform company built on the self-developed LNP and mRNA technology platforms. Based on these platforms, we will not be limited to a certain type of nucleic acid drug. Instead, we will continue to explore the application boundaries of LNP technology and mRNA technology and bring Best-in-Class and First-in-Class innovative drugs to clinical use.
The core elements and coding sequences of mRNA determine the stability of its binding to ribosomes, thereby affecting the efficiency and duration of protein translation.Innorna has identified the optimal ribosome-binding sequences through rational sequence design and optimization, enabling more efficient and long-lasting protein translation.
Innorna’s mRNA technology, which has been validated in NHP (non-human primate), has been one of the leaders in the world.
Extensive experience and know-how in LNP and mRNA
30+ approved/ pending global patents on mRNA/LNP
Innorna and BeiGene launched a strategic cooperation to jointly develop innovative mRNA products
Faced with the challenge of delivering mRNA into the correct cell, mRNA carriers have long been unable to maximize mRNA as a therapeutic tool capable of guiding cells to generate disease-fighting proteins. Innorna was able to develop the proprietary diversity-oriented LNP platform for safely and effectively delivering the mRNA into the right cells and commercializing this innovative technology. This enables a wide range of potential prophylactic and therapeutic strategies that we are using to advance a diversified portfolio of mRNA medicine pipelines．
Innorna has analyzed and optimized the synthesized LNP structure and activity data, simulated the nucleic acid drug delivery and therapeutic effect with high-throughput screening, and screened out the best-in-class LNP structures for specific needs. Since its establishment, Innorna has built a resource library containing over 5,000 LNPs for various treatment approaches.
messenger RNA (mRNA) is a type of single-strand ribonucleic acid that is transcribed from DNA (deoxyribonucleic acid). It carries genetic information and can guide protein synthesis. The mechanism of nucleic acid drugs is to send the modified mRNA molecules into the cytoplasm and generate the required proteins within target cells. In theory, mRNA can express any protein and, therefore, can prevent or treat almost all protein-based diseases, including infectious diseases, various types of cancer, autoimmune diseases, and some rare diseases. Importantly, mRNA acts as a link connecting DNA and proteins, and the development of drugs with mRNA targets is expected to resolve many of the limitations and challenges encountered in traditional drug development of “untargetable” and “unmanufacturable” drugs.
Innorna and PATH are exploring innovative mRNA vaccine technologies aiming to make such innovations more widely accessible.
ZFSW: Carrying out technical cooperation with Innorna, targeting mRNA R&D projects
Molecular diversity is the key to finding new functionalities of lipid nanoparticles. Innorna is committed to building a diversity-oriented lipid library (DOLL) to explore new functions of lipids, such as tissue specific delivery and molecules with low immunogenicity. By employing various chemical methods to build up the core structure of DOLL, we have successfully established a broad spectrum of molecular diversity, which significantly optimize the opportunities of finding new functional lipids than that from combinatorial libraries.
Innorna has become a platform company built on the self-developed LNP and mRNA technology platforms. Based on these platforms, we will not be limited to a certain type of nucleic acid drug. Instead, we will continue to explore the application boundaries of LNP technology and mRNA technology and bring Best-in-Class and First-in-Class innovative drugs to clinical use.
The core elements and coding sequences of mRNA determine the stability of its binding to ribosomes, thereby affecting the efficiency and duration of protein translation.Innorna has identified the optimal ribosome-binding sequences through rational sequence design and optimization, enabling more efficient and long-lasting protein translation.
Innorna’s mRNA technology, which has been validated in NHP (non-human primate), has been one of the leaders in the world.
Extensive experience and know-how in LNP and mRNA
30+ approved/ pending global patents on mRNA/LNP
